RSS Feeds
Search

Articles

Pharmalicensing brings you advice, commentary and analysis from industry experts.

Articles

No results found for given criteria.
Please try to put more general criteria into your selection.

Related Reports

Market Research Reports provided by reports.iptechex.com
Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)
May 2011 - 5 pages - $500
Lymphoma - Pipeline Review, Q3 2011
Jul 2011 - 672 pages - $500
Cutaneous T-Cell Lymphoma - Pipeline Review, Q4 2010
Dec 2010 - 47 pages - $500
Mantle Cell Lymphoma - Pipeline Review, Q3 2011
Jul 2011 - 268 pages - $500
Follicular Lymphoma - Pipeline Review, Q3 2011
Jul 2011 - 213 pages - $500
Indolent Lymphoma - Pipeline Review, Q4 2010
Dec 2010 - 45 pages - $500
Burkitt Lymphoma - Pipeline Review, Q4 2010
Dec 2010 - 26 pages - $500
Diffuse Large B-Cell Lymphoma - Pipeline Review, Q3 2011
Jul 2011 - 351 pages - $500
Cutaneous T-Cell Lymphoma - Pipeline Review, Q2 2011
Apr 2011 - 92 pages - $500
US Oncology, Inc.: SWOT Analysis & Company Profile
Dec 2010 - 19 pages - $99
More Related Market Research Reports >>>

Your selection

Industry sector
Drug discovery del
Therapeutic target
Oncology del
Lymphoma del
Year
2010 del

Browse By

Industry sector
Bioinformatics
Combinatorial biology
Combinatorial chemistry
Drug research platforms
Genomics
High throughput screening
Proteomics
Therapeutic target
Hodgkin's lymphoma
Lymphoma, AIDS-related
Neoplastic disease
Non-Hodgkins lymphoma

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us